• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:57:16 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care
    Get the next $GNMK alert in real time by email
    SC 13G/A 1 tv0946-genmarkdiagnosticsinc.htm SCHEDULE 13G/A genmarkdiagnosticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  GenMark Diagnostics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  372309104

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  372309104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    157,485

    7.  SOLE DISPOSITIVE POWER

    4,286,937

    8.  SHARED DISPOSITIVE POWER

    210,967

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,497,904

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.27%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    GenMark Diagnostics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5964 La Place Court
    Carlsbad, California 92008

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    372309104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    4,497,904

      (b) Percent of Class:

    6.27%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  157,485

    (iii)  sole power to dispose of or to direct the disposition of:  4,286,937

    (iv)  shared power to dispose or to direct the disposition of:  210,967

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $GNMK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNMK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giles Lisa M. decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:57 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fox James decreased direct ownership by 100% to 0 units to cover taxes

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:12 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Kagnoff Michael decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:32 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GNMK
    SEC Filings

    View All

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash

    Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

    3/25/21 12:40:00 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

    Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

    3/15/21 2:00:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by GenMark Diagnostics, Inc.

    15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

    5/3/21 4:02:03 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by GenMark Diagnostics, Inc.

    EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/28/21 12:15:09 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by GenMark Diagnostics, Inc.

    S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/22/21 4:22:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GenMark Diagnostics downgraded by BTIG

    BTIG downgraded GenMark Diagnostics from Buy to Neutral

    3/17/21 7:31:42 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Cowen & Co. with a new price target

    Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

    3/17/21 6:46:59 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Canaccord Genuity

    Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

    3/16/21 10:34:41 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    5/10/21 11:58:21 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    4/12/21 1:05:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by GenMark Diagnostics, Inc.

    SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

    3/26/21 9:07:58 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care